Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
The Challenge 
Using Big Data to Solve Big Problems
Advancing the Cardiovascular Health of Our Society
egnite is a digital health company leveraging artificial intelligence-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions.
Our Work
Groundbreaking New Data from the Largest Contemporary Analysis of Valvular Heart Disease Prevalence
Aligned with egnite’s mission to close gaps in structural heart patient care, egnite sponsored a study analyzing over 929,000 de-identified echocardiograms from 35 heart programs to further understand the prevalence of VHD in the U.S.
Brennan JM, Petrescu M, McCarthy P, et al. J Am Coll Cardiol. 2022;79(9_Suppl):1723.
Testimonials
Leading hospitals partner with egnite’s CardioCare platform to reduce variability in care and improve guideline-directed therapy for patients with cardiovascular disease.
Swedish Medical Center
Director of Structural Interventions, Stanford Health Care
Resources
Using AI and Big Data to Speed Up Cardiovascular Clinical Trials
Clinical trials are necessary to ensure the safety and efficacy of new therapies, but they can be time-consuming, costly and inefficient to enroll, slowing down access to lifesaving treatment options. The future of faster clinical trials is here.
egnite, Inc. and JenaValve Announce Strategic Partnership to Uncover Trends in Care for Patients with Aortic Regurgitation
Partnership aims to understand the care paradigm and associated outcomes for patients with aortic regurgitation. First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona.
egnite, Inc. Announces Research from its Real-World Database at Heart Rhythm 2023
Study Led by John Mignone, M.D., Ph.D., Presented at the Heart Rhythm Society’s Annual Meeting. Key Findings Demonstrate Increased Survival for Patients Receiving Combined Device and 4-Class Medical Therapy.